Targeting the Androgen Receptor in MBC - Metastatic Breast Cancer Trial Talk

Research News

Androgen receptors bind to male hormones called androgens. Females also produce small amounts of androgens. About 70% of estrogen receptor-positive (ER+) breast cancers and about 40% of triple-negative breast cancers (TNBC) express androgen receptors.

Research has shown that androgen receptors play a role in breast cancer cell growth. Therefore, drugs that target the androgen receptor are being studied in clinical trials as treatments for people with breast cancer, including MBC. These drugs are also being tested to overcome resistance to hormone therapy and CDK4/6 inhibitors.

Read below to learn more about research into drugs that target androgen receptors in MBC and find clinical trials for androgen receptor-positive breast cancer.

Drugs Targeting Androgen Receptors
Androgen Receptors in TNBC
Androgen Receptors in ER+ MBC
MBC Clinical Trials

Last Modified on April 1, 2024



for past articles or specific information.